Related Experiment Video

Updated: Dec 21, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.6K

The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease

Ali Bayoumi1, Henning Grønbæk2, Jacob George1

  • 1Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, NSW, Australia.

Trends in Genetics : TIG
|May 13, 2020
PubMed

Insights

Epigenetic dysregulation drives metabolic dysfunction-associated fatty liver disease (MAFLD). Targeting epigenetics offers a promising therapeutic avenue for MAFLD, with several drugs and biomarkers in development.

Area of Science:

  • Hepatology
  • Epigenetics
  • Metabolic Diseases

Background:

  • Metabolic dysfunction-associated fatty liver disease (MAFLD) lacks effective therapies.
  • Epigenetic dysregulation is increasingly recognized as a key factor in MAFLD development and progression.
  • Epigenetic modifications are plastic and responsive to environmental factors, presenting therapeutic opportunities.

Purpose of the Study:

  • To review recent advances in understanding epigenetic regulation in MAFLD.
  • To explore the translational potential and challenges of epigenetics in MAFLD therapy.

Main Methods:

  • Review of current literature on epigenetic mechanisms in MAFLD.
  • Analysis of DNA methylation, histone modifications, chromatin remodeling, transcriptional control, and noncoding RNAs.
  • Discussion of epigenetics-based drug and biomarker development.

Main Results:

  • Epigenetic dysregulation significantly contributes to MAFLD pathogenesis.
  • Epigenetic mechanisms offer novel targets for MAFLD treatment.
  • Several epigenetics-based drugs and diagnostic biomarkers are advancing in clinical development.

Conclusions:

  • Epigenetics represents a promising frontier for MAFLD therapeutic strategies.
  • Translational challenges in epigenetics for MAFLD require further investigation.
  • Targeting epigenetic modifications holds potential for improved MAFLD management.
Keywords:
DNA methylationMAFLDNAFLDepigeneticsfibrosis

More Related Videos

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.6K
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.5K

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.7K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
115
Overview of Fatty Acid Metabolism01:28

Overview of Fatty Acid Metabolism

Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
35.9K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
143
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.3K